The pharmaceutical industry's battle for dominance in the fast-growing and lucrative market for treatments of hepatitis C is prompting an unprecedented legal scramble.. The prospect that hepatitis-C drug sales could soar to $20 billion annually by the end of the decade is spurring attempts by drug companies to assert the patent rights they'll need to grab a piece of the pie. . The...
  